GGHSX — Invesco Health Care Fund
Data updated: 2026-09-28
GGHSX — Invesco Health Care Fund. United States Large Cap Blend / Core Health Care Equity · $1.21B AUM. Holdings, fees, performance and SEC filings.
GGHSX Fund Overview
GGHSX — Invesco Health Care Fund is a US mutual fund managed by Aim Investment Funds (invesco Investment Funds), categorised as United States Large Cap Blend / Core Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Aim Investment Funds (invesco Investment Funds)
- Category: United States Large Cap Blend / Core Health Care Equity
- Assets under management: $1.21B
- 1-year return: 17.5%
- Ticker: GGHSX
- SEC CIK: 0000826644
- SEC series ID: S000000235
- Share class ID: C000188882
GGHSX Investment Objective and Strategy
Invesco Health Care Fund describes its objective and strategy as follows, from its latest prospectus filed with the SEC by Aim Investment Funds (invesco Investment Funds).
Investment objective
The Fund’s investment objective is long-term growth of capital.
Principal investment strategy
The Fund invests, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of issuers engaged primarily in health care-related industries, and in derivatives and other instruments that have economic characteristics similar to such securities. The Fund uses various criteria to determine whether an issuer is engaged in health care-related industries, including whether (1) it derives 50% or more of its gross income or its net sales from activities in the health care industry; (2) it devotes 50% or more of its assets to producing revenues from the health care industry; or (3) based on other available information, the Funds portfolio managers determine that its primary business is within the health care industry. Issuers engaged in health care-related industries include those that design, manufacture, or sell products or services used for or in connection with health care or medicine (such as pharmaceutical issuers, biotechnology research firms, companies that sell medical products, and companies that own or operate health care facilities).
The Fund invests primarily in equity securities, securities convertible into equity securities, and depositary receipts. The principal types of equity securities in which the Fund invests are common and preferred stock. The Fund may invest in the securities of issuers of all capitalization sizes and may invest a significant amount of its net assets in the securities of small- and mid-capitalization issuers. Under normal circumstances, the Fund will provide exposure to investments that are economically tied to at least three different countries, including the U.S. The Fund may invest up to 20% of its net assets in securities of issuers located in emerging markets countries, i.e., those that are in the early stages of their industrial cycles. The Fund can invest in derivative instruments, including forward foreign currency contracts.
The Fund can use forward foreign currency contracts to hedge against adverse movements in the foreign currencies in which portfolio securities are denominated. In selecting securities for the Fund, the portfolio managers first screen the global investment universe. Securities of issuers with a minimum market capitalization threshold are considered for further evaluation if they are identified as having attractive growth prospects relative to their current valuations. The portfolio managers use a research-oriented bottom-up investment approach, focusing on issuer fundamentals in an effort to uncover future growth prospects which are not yet appreciated by the market. In analyzing specific industries, the portfolio managers ordinarily look for above-average growth and demand; below-average reimbursement risk; and high barriers to entry.
In analyzing specific issuers, the portfolio managers ordinarily look for leading issuers with defensible franchises; issuers with a solid 18- to 24-month outlook; value-added and/or niche-oriented products and/or services; potential to expand margins and improve profitability; superior earnings-per-share growth; a strong balance sheet and moderate financial leverage; and a capable management team and potential for downside risks. Security selection is then further refined by valuation analysis. In general, the portfolio managers target securities trading at attractive valuations based upon one or more of the following parameters: price-to-earnings (P/E); P/E ratio versus expected earnings per share growth rate; enterprise value to earnings before interest depreciation and taxes (EBITDA); discounted cash flow analysis; sum of parts analysis and asset/scarcity value.
Additionally, position size is limited in an effort to maximize risk-adjusted returns. The portfolio managers will consider selling the security of an issuer if, among other things, (1) a securitys price reaches its valuation target; (2) an issuers fundamentals deteriorate; or (3) if more compelling opportunities exist.
GGHSX Holdings
Top 10 holdings of Invesco Health Care Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Eli Lilly and Co. | 10.59% |
| Johnson & Johnson | 6.76% |
| UnitedHealth Group Inc. | 6.17% |
| Invesco Private Prime Fund | 4.67% |
| Merck & Co., Inc. | 4.59% |
| AbbVie Inc. | 4.03% |
| Gilead Sciences, Inc. | 3.63% |
| argenx SE | 3.24% |
| CVS Health Corp. | 2.52% |
| Welltower Inc. | 2.34% |
GGHSX Portfolio Allocation
Asset-class allocation of Invesco Health Care Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 97.5% |
| Cash & Equivalents | 8.8% |
GGHSX Performance
Total returns for GGHSX (as of 2026-10-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 2.1% |
| 1 year | 17.5% |
| 3 years (annualised) | 7.9% |
| 5 years (annualised) | 2.8% |
GGHSX Risk Information
Risk metrics for GGHSX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 15.8%
GGHSX Costs and Fees
GGHSX costs about $72 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.72%
- Gross expense ratio: 0.72%
- Portfolio turnover: 56%
- Brokerage commissions: 4.24 bps of average net assets (SEC N-CEN)
GGHSX Cashflows
Over the 12 months to 2026-07, Invesco Health Care Fund had net outflows of $57.39M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-07 | −$1.91M |
| 2026-06 | −$8.51M |
| 2026-05 | −$13.05M |
| 2026-04 | −$12.07M |
| 2026-03 | −$10.45M |
| 2026-02 | −$8.67M |
GGHSX Debt Constituents
No individual debt constituents are reported in Invesco Health Care Fund's latest SEC N-PORT filing.
GGHSX Prospectus and SEC Filings
Official Invesco Health Care Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2026-02-27
- Prospectus (485BPOS) — filed 2025-08-28
- Prospectus (485BPOS) — filed 2025-02-28
- Portfolio holdings (N-PORT) — filed 2026-09-28
- Portfolio holdings (N-PORT) — filed 2026-06-26
- Portfolio holdings (N-PORT) — filed 2026-04-01
- Annual census (N-CEN) — filed 2026-01-14
- Annual census (N-CEN) — filed 2025-01-14
Related Funds
Other United States Large Cap Blend / Core Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.